BioSpace News Archive

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of Directors, effective July 19, 2021.

Cytokinetics, Incorporated announced plans to offer, subject to market and other conditions, $200,000,000 of shares of its common stock in an underwritten public offering.

Ardelyx, Inc. today announced that it received a letter from the U.S. Food and Drug Administration on July 13, 2021, stating that, as part of its ongoing review of the company’s New Drug Application (“NDA”) for the control of serum phosphorus in adult patients with chronic kidney disease (“CKD”) on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.

South Korea-based biotech company, Ubix Therapeutics (en.ubixtrx.com), announced the current status of their lead program, UBX-303, which utilizes Ubix’s platform technology, Degraducer®.

AB Science SA today announced publication of a paper titled Long-term Survival Analysis of Masitinib in Amyotrophic Lateral Sclerosis’ in the peer-reviewed journal Therapeutic Advances in Neurological Disorders (TAND) [1].

Vista Apex, a leading manufacturer of endodontic solutions and restorative materials, pushes for change in the dental industry by developing innovative bio-regenerative alternatives to traditional dental materials.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented four posters at the International Society for Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress, being held July 17-21, 2021.

Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its second quarter 2021 financial results on Tuesday, August 3, 2021, at 4:30pm Eastern Time.

Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company’s Board of Directors

The global Immuno-oncology therapy market accounted for USD 62.2 Billion in 2020 and is expected to reach USD 194.9 Billion by 2028, growing at a CAGR of around 15% between 2021 and 2028.